Role of Survivin in Bladder Cancer: Issues to Be Overcome When Designing an Efficient Dual Nano-Therapy
Bladder cancer is the 10th most diagnosed cancer, with almost 10 M cancer deaths last year worldwide. Currently, chemotherapy is widely used as adjuvant therapy after surgical transurethral resection. Paclitaxel (PTX) is one of the most promising drugs, but cancer cells acquire resistance, causing f...
Guardado en:
Autores principales: | Maria Arista-Romero, Anna Cascante, Cristina Fornaguera, Salvador Borrós |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ac3c8783abf7463ebdc2734df51408c8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes
por: Jin M, et al.
Publicado: (2018) -
Wild type, dEX3 and 2B survivin isoforms localize to the tumor cell plasma membrane, are secreted in exosomes, and interact with extracellular tubulin
por: Sheila Figel, et al.
Publicado: (2021) -
Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy
por: Bi Y, et al.
Publicado: (2018) -
Improvement of Paclitaxel-Associated Adverse Reactions (ADRs) via the Use of Nano-Based Drug Delivery Systems: A Systematic Review and Network Meta-Analysis
por: Chou PL, et al.
Publicado: (2020) -
Efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene
por: Luo L, et al.
Publicado: (2016)